No Data
No Data
BTIG Maintains Outlook Therapeutics(OTLK.US) With Buy Rating, Maintains Target Price $50
BTIG analyst Julian Harrison maintains $Outlook Therapeutics(OTLK.US)$ with a buy rating, and maintains the target price at $50.According to TipRanks data, the analyst has a success rate of 46.1%
Express News | Outlook Therapeutics® Announces UK Mhra Marketing Authorization of Lytenava™ (Bevacizumab Gamma) for the Treatment of Wet AMD
Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) Largest Shareholders Are Individual Investors With 31% Ownership, Private Equity Firms Own 31%
Outlook Therapeutics(R) (NASDAQ: OTLK) to Participate Virtual Investor Closing Bell Series
Outlook Therapeutics to Present at the Virtual Investor Pitch Conference
Outlook Therapeutics(R) (NASDAQ:OTLK) Participates in Virtual Investor "What This Means" Segment Hosted by JTC Team
Watch the "What This Means" video hereOutlook CEO, Russ Trenary underscores that LYTENAVA (bevacizumab gamma) has become the first ophthalmic formulation of bevacizumab to receive European Commission